Unit Price:
৳ 40.00
(1 x 10: ৳ 400.00)
Strip Price:
৳ 400.00
Also available as:
Indications
Emfogen is indicated in:
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Pharmacology
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Dosage & Administration
The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empagliflozin is recommended.
Interaction
Diuretics: Co-administration of Emfogen with diuretics resulted in increased urine volume.
Insulin or Insulin Secretagogues: Co-administration of Emfogen with insulin or insulin secretagogues increases the risk for hypoglycemia.
Positive Urine Glucose Test: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.
Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.
Insulin or Insulin Secretagogues: Co-administration of Emfogen with insulin or insulin secretagogues increases the risk for hypoglycemia.
Positive Urine Glucose Test: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.
Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.
Contraindications
Empagliflozin is contraindicated in patients with history of serious hypersensitivity reaction to Empagliflozin or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.
Side Effects
The most common adverse reactions associated with Emfogen are urinary tract infections and female genital mycotic infections. Others common side effects includes dehydration, hypotension, weakness, dizziness and increased thirstiness.
Pregnancy & Lactation
There are no adequate and well-controlled studies of Empagliflozin in pregnant women. Empagliflozin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empagliflozin is excreted in human milk. It is not recommended when breastfeeding.
Precautions & Warnings
Assessment of renal function is recommended prior to initiation of Emfogen and periodically thereafter. Emfogen should not initiated in patients with an eGFR less than 45 ml/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.
Overdose Effects
In the event of an overdose with Emfogen the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Emfogen by hemodialysis has not been studied.
Therapeutic Class
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
Keep in a cool & dry place (below 30° C), protected from light & moisture. Keep out of the reach of children.
Chemical Structure
| Molecular Formula : | C23H27ClO7 |
| Chemical Structure : |  |
Common Questions about Emfogen 25 mg Tablet
What is Emfogen 25 mg Tablet?
Emfogen 25 mg Tablet is a SGLT-2 inhibitor which reduces the reabsorption of glucose from kidney.
What is Emfogen 25 mg Tablet used for?
Emfogen 25 mg Tablet is commonly used to improve glycemic control in adults.
Are there any pregnancy warnings?
Emfogen 25 mg Tablet may be unsafe to use during pregnancy.
Are there any breast-feeding warnings?
Emfogen 25 mg Tablet is probably unsafe to use during breastfeeding.
Does this affect kidney function?
Emfogen 25 mg Tablet should be used cautiously in patients with an underlying kidney disease.
Does this affect liver function?
No dose adjustment is needed for patients with the mild to moderate liver disease.
Quick Tips
- Emfogen 25 mg Tablet is used alone or together with other diabetes medicines to control blood sugar and avoid long-term complications.
- Emfogen 25 mg Tablet may cause your body to lose too much fluid (dehydration) or you may urinate more often. Drink plenty of water and stay hydrated.
- Emfogen 25 mg Tablet may cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines, alcohol or if you delay or miss a meal.
- Always carry some sugary food or fruit juice with you in case you experience hypoglycemia symptoms such as cold sweats, cool pale skin, tremor and anxiety.
- Emfogen 25 mg Tablet can cause genital fungal and/or urinary tract infections (UTIs) in both females and males, so practice good hygiene.
- Monitor your blood sugar regularly while taking Emfogen 25 mg Tablet.
- Inform your doctor immediately if you experience constant dizziness, joint pain, cold-like symptoms or unexplained nausea/vomiting.
Pack Image: Emfogen 25 mg Tablet